Novartis has introduced today at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Berlin, data related to a clinical trial assessing Gilenya (fingolimod), an oral therapy for MS, in addition to the investigational therapy siponimod (BAF312), reported to reduce the risk of disease progression. On the occasion, the Switzerland-based group will provide an update about the progress made in assessing the efficacy of investigational therapy ofatumumab (OMB157), currently tested in a Phase III trial. Additionally, Novartis will report some scientific evidence about new systems to measure the concentration of protein neurofilaments usually found in the blood of MS patients due to damage to neurons. Data concerning concentration of protein neurofilaments are fundamental to objectively assess the disease stage. MS is an autoimmune disease that may become highly disabling. It affects approximately 2.3 million individuals in the world.